Background: Chronic spontaneous urticaria (CSU) is an autoimmune skin disorder that lasts for >6 weeks and may last for years. It is a disabling skin disease that impairs quality of life. Set-up treatment with antihistamines, immunosuppressives, immune modulators and lately Omalizumab are expensive or have significant side effects. In this retrospective study, we describe our experience with the use of hydroxychloroquine (HCQ) as a maintenance therapy for those with severe forms of CSU after Corticosteroids (C) induction phase. Patients and Methods: 16 adult patients (aged 44 ± 7) with severe CSU for 5 ± 1 months, were included in the study. Eight patients had attacks of angioneurotic oedema. Their previous treatments were antihistaminic and short-courses of C. Results: After 2 weeks of remission with C and HCQ 200 mg twice daily, the dose of C was tapered down and discontinued by the end of the first month. The seven days Urticaria Activity Score decreased from 30 ± 3 to 6 ± 1 by the first month and remained low at 3 ± 1 by the end of 2 years of follow-up. Moreover, IgE levels and CRP had similar trends. Remission persisted after 37 ± 9 months of follow-up. Conclusion: HCQ is a safe, efficacious and inexpensive drug for the treatment of CSU.
References
[1]
Greaves, M. (2000) Chronic Urticaria. Journal of Allergy and Clinical Immunology, 105, 664-672. https://doi.org/10.1067/mai.2000.105706
[2]
Zuberbier, T., Abdul Latiff, A.H., Abuzakouk, M., Aquilina, S., Asero, R., Baker, D., et al. (2021) The International EAACI/Ga²Len/EuroGuiDerm/APAAACI Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria. Allergy, 77, 734-766. https://doi.org/10.1111/all.15090
[3]
Maurer, M., Weller, K., Bindslev-Jensen, C., Giménez-Arnau, A., Bousquet, P.J., Bousquet, J., et al. (2010) Unmet Clinical Needs in Chronic Spontaneous Urticaria. A GA2LEN Task Force Report. Allergy, 66, 317-330. https://doi.org/10.1111/j.1398-9995.2010.02496.x
[4]
Godse, K., Mehta, A., Patil, S., Gautam, M. and Nadkarni, N. (2015) Omalizumab—A review. Indian Journal of Dermatology, 60, 381-384. https://doi.org/10.4103/0019-5154.160490
[5]
McKeage, K. (2013) Omalizumab: A Review of Its Use in Patients with Severe Persistent Allergic Asthma. Drugs, 73, 1197-1212. https://doi.org/10.1007/s40265-013-0085-4
[6]
Yasir, M., Goyal, A. and Sonthalia, S. (2023) Corticosteroid Adverse Effects. StatPearls Publishing.
[7]
Zuberbier, T., Aberer, W., Asero, R., Bindslev-Jensen, C., Brzoza, Z., Canonica, G.W., et al. (2014) The EAACI/GA2 LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria: The 2013 Revision and Update. Allergy, 69, 868-887. https://doi.org/10.1111/all.12313
[8]
Ponsford, M.J., Klocperk, A., Pulvirenti, F., Dalm, V.A.S.H., Milota, T., Cinetto, F., et al. (2018) Hyper‐IgE in the Allergy Clinic—When Is It Primary Immunodeficiency? Allergy, 73, 2122-2136. https://doi.org/10.1111/all.13578
[9]
Mouliou, D.S. (2023) C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians. Diseases, 11, Article 132. https://doi.org/10.3390/diseases11040132
[10]
Holm, J.G., Ivyanskiy, I. and Thomsen, S.F. (2017) Use of Nonbiologic Treatments in Antihistamine-Refractory Chronic Urticaria: A Review of Published Evidence. Journal of Dermatological Treatment, 29, 80-97. https://doi.org/10.1080/09546634.2017.1329505
[11]
Kaplan, A., Ferrer, M., Bernstein, J.A., Antonova, E., Trzaskoma, B., Raimundo, K., et al. (2016) Timing and Duration of Omalizumab Response in Patients with Chronic Idiopathic/Spontaneous Urticaria. Journal of Allergy and Clinical Immunology, 137, 474-481. https://doi.org/10.1016/j.jaci.2015.08.023
[12]
Nirk, E.L., Reggiori, F. and Mauthe, M. (2020) Hydroxychloroquine in Rheumatic Autoimmune Disorders and Beyond. EMBO Molecular Medicine, 12, e12476. https://doi.org/10.15252/emmm.202012476
[13]
Khan, N., Epstein, T.G., DuBuske, I., Strobel, M. and Bernstein, D.I. (2022) Effectiveness of Hydroxychloroquine and Omalizumab in Chronic Spontaneous Urticaria: A Real-World Study. The Journal of Allergy and Clinical Immunology: In Practice, 10, 3300-3305. https://doi.org/10.1016/j.jaip.2022.08.051
[14]
Kolkhir, P., Altrichter, S., Munoz, M., Hawro, T. and Maurer, M. (2020) New Treatments for Chronic Urticaria. Annals of Allergy, Asthma & Immunology, 124, 2-12. https://doi.org/10.1016/j.anai.2019.08.014
[15]
Ertas, R., Ozyurt, K., Atasoy, M., Hawro, T. and Maurer, M. (2017) The Clinical Response to Omalizumab in Chronic Spontaneous Urticaria Patients Is Linked to and Predicted by IgE Levels and Their Change. Allergy, 73, 705-712. https://doi.org/10.1111/all.13345
[16]
Kolkhir, P., Altrichter, S., Hawro, T. and Maurer, M. (2017) C‐Reactive Protein Is Linked to Disease Activity, Impact, and Response to Treatment in Patients with Chronic Spontaneous Urticaria. Allergy, 73, 940-948. https://doi.org/10.1111/all.13352
[17]
Mariuzza, R.A., Agnihotri, P. and Orban, J. (2020) The Structural Basis of T-Cell Receptor (TCR) Activation: An Enduring Enigma. Journal of Biological Chemistry, 295, 914-925. https://doi.org/10.1016/s0021-9258(17)49904-2
[18]
Goldman, F.D., Gilman, A.L., Hollenback, C., Kato, R.M., Premack, B.A. and Rawlings, D.J. (2000) Hydroxychloroquine Inhibits Calcium Signals in T Cells: A New Mechanism to Explain Its Immunomodulatory Properties. Blood, 95, 3460-3466. https://doi.org/10.1182/blood.v95.11.3460
